Belite Bio, Inc American Depositary Shares BLTE
Analyst Ratings
- Consensus
- Buy — 7 Buy · 0 Hold · 0 Sell (7 analysts)
- Avg. Price Target
- $226.43 (+58.6% upside)
Key Stats
- Today's Range
- $141.62 – $152.62
- 50-Day Range
- $141.62 – $198.58
- 52-Week Range
- $64.80 – $200.00
- Volume
- 194K shs
- Average Volume
- 201K shs
- Market Cap
- $5.75 billion
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.14%
- Days to Cover
- 1.00
About Belite Bio, Inc American Depositary Shares
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
Related Stocks
Compare head-to-head: BLTE vs NVDA·BLTE vs AAPL·BLTE vs GOOGL·BLTE vs GOOG
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.